A new migraine medication is on the horizon Lundbeck Therapeutics is testing a monoclonal antibody that targets a novel neuropeptide in a Phase 2b clinical trial.

https://www.drugdiscoverynews.com/a-new-migraine-medication-is-on-the-horizon-16238